PANews reported on February 2nd that Hyperliquid announced on its X platform that HyperCore will support "Outcome Trading" (HIP-4). Outcomes are fully collateralizedPANews reported on February 2nd that Hyperliquid announced on its X platform that HyperCore will support "Outcome Trading" (HIP-4). Outcomes are fully collateralized

Hyperliquid announced that HyperCore will support "Outcome Transactions" (HIP-4).

2026/02/02 22:21
1 min read

PANews reported on February 2nd that Hyperliquid announced on its X platform that HyperCore will support "Outcome Trading" (HIP-4). Outcomes are fully collateralized contracts that settle within a fixed range. It's a general-purpose foundational component suitable for applications such as prediction markets and option-like finite instruments. Outcome trading introduces non-linear characteristics, periodic contracts, and a new form of derivatives trading without leverage or liquidation. This foundational component expands HyperCore's expressive power and can work in conjunction with other components such as portfolio margin and HyperEVM. Outcome contracts are currently under development and are only being tested on the testnet. A standardized market based on objective settlement sources will be deployed after the technology development is complete. The standardized market will be denominated in USDH. Based on user feedback, the infrastructure will be gradually rolled out to a permissionless deployment mode.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.